Special Episode: Oncology After COVID-19
In season 2, episode 4 of “Targeted Talks,” Benjamin O. Anderson, MD, FACS, discussed the lessons learned from the COVID-19 pandemic, and preparation for a post-COVID America.
In season 2, episode 4 of “Targeted Talks,” Benjamin O. Anderson, MD, FACS, of the World Health Organization and Fred Hutchinson Cancer Research Center joins our host for a recap interview around a recent Targeted Oncology webinar, “Lessons Learned in Pathology and Oncology From the COVID-19 Pandemic.”
According to Anderson, the COVID-19 pandemic revealed great opportunities within our health care system, like telemedicine, which has increased since the pandemic began and is likely to continue in the future. The pandemic also revealed some weaknesses within the health care infrastructure that will have to be addressed after the pandemic as a method of readiness for future crises.
Part of improving the United States health care system, according to Anderson, is understanding that different patient populations have different resources and coming up with a plan that works for all groups.
Jhaveri Compares Safety and Duration of Adjuvant CDK4/6 Inhibitors in HR+ Breast Cancer
December 22nd 2024During a Case-Based Roundtable® event, Komal Jhaveri, MD, FACP, discussed dosing and toxicity concerns with the approved CDK4/6 inhibitor regimens used in the adjuvant setting for patients with hormone receptor–positive breast cancer.
Read More
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC
December 21st 2024During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.
Read More
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen
Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers
December 20th 2024During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.
Read More
